Foghorn Therapeutics (FHTX)
(Delayed Data from NSDQ)
$5.00 USD
-0.14 (-2.72%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $4.99 -0.01 (-0.20%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
FHTX 5.00 -0.14(-2.72%)
Will FHTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FHTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FHTX
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Lags Revenue Estimates
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates
FHTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates
Other News for FHTX
FHTX: Upcoming Virtual Meeting Hosted by B. Riley
Foghorn Therapeutics management to meet virtually with B. Riley
Foghorn Therapeutics reports Q2 results
Foghorn Therapeutics Inc (FHTX) Q2 2025 Earnings: EPS of -$0.33 Meets Estimates, Revenue of $7. ...
FHTX Reports Strong Q2 Revenue and Advances Cancer Treatment Pipeline